摘要
目的 :研究多药耐药基因 mdr-1和凋亡抑制基因 bcl-2对白血病预后的影响。方法 :用免疫组织化学染色方法检测白血病患者 P-糖蛋白 ( Pgp)和 bcl-2蛋白的表达 ,分析其与化疗效果的关系。结果 :在 15 4例急性白血病患者中 ,Pgp和 bcl-2蛋白表达的阳性率分别为 47.4%和 72 .1% ,与 FAB分型无关。复发患者的 Pgp阳性率( 6 4.6 % )高于初治患者 ( 39.6 % ) ( P<0 .0 1) ,bcl-2阳性率在初治与复发患者之间无显著差异。Pgp和 bcl-2蛋白表达均阳性者完全缓解率 ( 2 5 % )低于 Pgp和 bcl-2蛋白表达均阴性者 ( 6 3.6 % ) ( P<0 .0 5 )。结论 :Pgp和 bcl-2蛋白联合检测对评价急性白血病的预后具较大的临床意义。
Objective:To investigate the effect of P glycoprotein (Pgp) and bcl 2 protein on prognosis in acute leukemia.Methods:Expression of Pgp and bcl 2 protein was measured by immunohistochemistry,and the relationship between the expression of P glycoprotein (Pgp) and bcl 2 and effect of chemotherapy was analyzed.Results:In 154 patients with acute leukemia,the positive percentage of Pgp and bcl 2 were 47.4% and 72.1%,respectively.There were no correlation between expression of Pgp and bcl 2 protein and FAB subtype.The positive percentage of Pgp on relapse (64.6%) was significantly higher than that at previously untreated patients (39.6%) ( P <0.01).There was no significant difference in the positive percentage of bcl 2 between the relapse and previously untreated patients.The overall CR rate in patients with Pgp +/bcl 2 +(25%) is lower than that in patients with Pgp /bcl 2 (63.6%)( P <0.05).Conclusion:The measurement of Pgp combined with bcl 2 may be more valuable to evaluate the prognosis of acute leukemia.
出处
《白血病．淋巴瘤》
CAS
2001年第6期352-354,共3页
Journal of Leukemia & Lymphoma
基金
辽宁省自然科学基金 (962 3 0 3)
辽宁省科委研究基金(9 680 2 0 0 6)
